| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, R&D | SVP, Research And Development
1 company
Glenn Gregory M serves as a President, R&D at NVAX. Across recent SEC filings that breaks down to 16 buys and 350 sells. Those positions are worth an estimated $120K at current prices.
Historically, Glenn Gregory M's trades have earned a strong insider score of 88/100 across 34 rated trades. Over a 12-month horizon, 91.2% of those trades were profitable, with an average 12-month return of +73.2%.
The biggest single holding is NVAX (~$120K) as President, R&D. The recent filings there lean toward selling, a net 272,955 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2023 | NVAX Novavax Inc | President, R&D | Buy | 6,000 | $7.17 | $43,041.50 | +70.8% | +17.9% | -16.4% | |
| Dec 15, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 1,686 | $174.13 | $293,583.77 | -22.9% | -58.9% | -93.7% | |
| Dec 7, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 8,250 | $170.14 | $1,403,630.88 | -67.0% | -61.9% | -90.6% | |
| Nov 30, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 8,447 | $203.91 | $1,722,421.23 | -67.5% | -60.0% | -92.1% | |
| Nov 26, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 2,083 | $218.07 | $454,246.79 | -33.9% | -63.3% | -92.4% | |
| Nov 23, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 8,250 | $199.50 | $1,645,913.72 | -67.0% | -60.4% | -91.5% | |
| Nov 16, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 9,433 | $169.79 | $1,601,675.51 | -69.9% | -53.0% | -87.4% | |
| Nov 9, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 8,250 | $167.53 | $1,382,159.89 | -67.0% | -44.0% | -89.0% | |
| Nov 2, 2021 | NVAX Novavax Inc | President, R&D | Sale+OE | 8,250 | $183.82 | $1,516,551.77 | -67.0% | -52.0% | -89.5% | |
| Oct 29, 2021 | NVAX Novavax Inc | President, R&D | Sell | 680 | $148.34 | $100,871.05 | -14.3% | -51.0% | -84.5% |